Trial · NCT00630955

Family History Study of Alcohol Consumption Using Memantine

NCT00630955, Phase 2, Completed, Yale University; results first posted 2014-03-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Family History Study of Alcohol Consumption Using Memantine. Trials, record NCT00630955. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00630955

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Family History Study of Alcohol Consumption Using Memantine
NCT number: NCT00630955
Status: Completed
Phases: Phase 2
Enrollment: 111 participants, actual
Lead sponsor: Yale University
Conditions: Alcohol Drinking
Interventions: memantine, Memantine, Placebo
First posted: 2008-03-07
Last updated: 2020-03-17
Results first posted: 2014-03-05

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Drinks Consumed on Day 7	Day 7
Primary	Baseline-adjusted Craving (YCS)	Day 7	Craving for alcohol based on Yale Craving Scale, scores ranging from 0-112 mm on a visual analog scale, with higher measurements indicating higher craving. The baseline-adjusted craving is change score from baseline at Day 7.
Secondary	Stimulation Responses to Alcohol	Day 7	Brief Biphasic Alcohol Effects Scale-Stimulation subscale, measuring stimulation effects of alcohol on Day 7, 6 items, 11-point rating scale from 0=Not at All to 10=Extremely, total scores ranging from 0 - 30, with higher measurements indicating higher stimulation.
Secondary	Sedation Responses to Alcohol	Day 7	Brief Biphasic Alcohol Effects Scale-Sedation subscale, measuring sedation effects of alcohol on Day 7, 6 items, 11-point rating scale from 0=Not at All to 10=Extremely, total scores ranging from 0 - 30, with higher measurements indicating higher sedation.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Drinks Consumed on Day 7	Day 7		standard drinks	MEAN
PRIMARY	Baseline-adjusted Craving (YCS)	Day 7		millimeters	LEAST_SQUARES_MEAN
SECONDARY	Stimulation Responses to Alcohol	Day 7	Analysis includes all those who had complete data, which is less than those listed in the Participant Flow module	units on a scale	MEAN
SECONDARY	Sedation Responses to Alcohol	Day 7	Analysis includes all those who had complete data, which is less than those listed in the Participant Flow module	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Drinks Consumed on Day 7	0 mg Memantine	5.84	Standard Deviation 3.67	standard drinks
Number of Drinks Consumed on Day 7	20 mg Memantine	5.61	Standard Deviation 4.6	standard drinks
Number of Drinks Consumed on Day 7	40 mg Memantine	6.21	Standard Deviation 4.61	standard drinks
Baseline-adjusted Craving (YCS)	0 mg Memantine	20.2	Standard Error 2.16	millimeters
Baseline-adjusted Craving (YCS)	20 mg Memantine	14.1	Standard Error 2.23	millimeters
Baseline-adjusted Craving (YCS)	40 mg Memantine	21.4	Standard Error 2.23	millimeters
Stimulation Responses to Alcohol	0 mg Memantine	4.643	Standard Deviation 4.923	units on a scale
Stimulation Responses to Alcohol	20 mg Memantine	4.321	Standard Deviation 5.313	units on a scale
Stimulation Responses to Alcohol	40 mg Memantine	6.444	Standard Deviation 6.536	units on a scale
Sedation Responses to Alcohol	0 mg Memantine	3.286	Standard Deviation 5.381	units on a scale

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	0 mg Memantine	34
Overall Study	STARTED	20 mg Memantine	37
Overall Study	STARTED	40 mg Memantine	40
Overall Study	COMPLETED	0 mg Memantine	31
Overall Study	COMPLETED	20 mg Memantine	31
Overall Study	COMPLETED	40 mg Memantine	28
Overall Study	NOT COMPLETED	0 mg Memantine	3
Overall Study	NOT COMPLETED	20 mg Memantine	6
Overall Study	NOT COMPLETED	40 mg Memantine	12

Source ClinicalTrials.gov

Adverse events27

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal Pain	Gastrointestinal disorders	0 mg	6	34
other	Abdominal Pain	Gastrointestinal disorders	20 mg	2	37
other	Abdominal Pain	Gastrointestinal disorders	40 mg	3	40
other	nausea	Gastrointestinal disorders	0 mg	9	34
other	nausea	Gastrointestinal disorders	20 mg	5	37
other	nausea	Gastrointestinal disorders	40 mg	10	40
other	vomit	Gastrointestinal disorders	0 mg	5	34
other	vomit	Gastrointestinal disorders	20 mg	2	37
other	vomit	Gastrointestinal disorders	40 mg	0	40
other	Headache	General disorders	0 mg	9	34

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	0 mg
Total, all-cause mortality	20 mg
Total, all-cause mortality	40 mg
Total, other adverse events	0 mg	22	34
Total, other adverse events	20 mg	24	37
Total, other adverse events	40 mg	31	40
Total, serious adverse events	0 mg	0	34
Total, serious adverse events	20 mg	0	37
Total, serious adverse events	40 mg	0	40

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P50AA012870	Center for the Translational Neuroscience of Alcohol	Krystal, John H.	YALE UNIVERSITY	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2001 to 2026

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00630955

GET https://conductscience.org/api/trials/v1/NCT00630955/events?page=2

API reference For AI assistants